从痣到黑色素瘤的距离有多远?

2014-12-22 伊文 科学人说科学

黑色素瘤 起源于黑色素细胞;发生于皮肤和黏膜;进展快,死亡率高;人种差异明显 黑色素瘤的“ABCDE” Asymmetry 不对称性 Border 边缘 Color 颜色 Diameter 直径 Evolving 进展  “丑小鸭理论” 该痣在同一个体中观察越来越像彼此,而MM经常偏离本痣图案。这种临床实现指向不仅评估病变有关的形态,但也比较来周围病变,寻找

黑色素瘤

起源于黑色素细胞;发生于皮肤和黏膜;进展快,死亡率高;人种差异明显

黑色素瘤的“ABCDE”

Asymmetry 不对称性 Border 边缘 Color 颜色 Diameter 直径 Evolving 进展

 “丑小鸭理论”

在同一个体中观察越来越像彼此,而MM经常偏离本痣图案。这种临床实现指向不仅评估病变有关的形态,但也比较来周围病变,寻找在类似显现摩尔的背景的离群值的重要性。例如,该离群病变可以比周围的摩尔(图1A)放大和更暗,或者相反地,小型和红中的多个大的暗摩尔(图1B)的背景。最后,如果患者具有很少或没有其他摩尔(图1C),任何改变病变应被视为可疑异常值。

不同组织来源的肿瘤恶性进程不同

基因改变影响信号通路

早期诊断与早期治疗

完整切除;辅以放疗、免疫治疗;靶向治疗

最后,那么肿瘤消退是好现象吗?

        常见于水平生长期肿瘤;肿瘤部分消退与较薄黑色素瘤早期转移相关;


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680265, encodeId=ab39168026573, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Oct 31 12:17:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487607, encodeId=c12d148e6078f, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558681, encodeId=318c155868193, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564690, encodeId=8bec15646901f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-10-31 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680265, encodeId=ab39168026573, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Oct 31 12:17:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487607, encodeId=c12d148e6078f, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558681, encodeId=318c155868193, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564690, encodeId=8bec15646901f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2014-12-24 yese
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680265, encodeId=ab39168026573, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Oct 31 12:17:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487607, encodeId=c12d148e6078f, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558681, encodeId=318c155868193, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564690, encodeId=8bec15646901f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680265, encodeId=ab39168026573, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Oct 31 12:17:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487607, encodeId=c12d148e6078f, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558681, encodeId=318c155868193, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564690, encodeId=8bec15646901f, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]

相关资讯

NEJM: Dabrafenib与Trametinib联用提高黑色素瘤患者的总生存率

研究背景: 促分裂素原活化蛋白激酶 (MAPK) 信号转导通路是细胞内最重要的信号通路之一, 该通路通过RAS、RAF、有丝分裂原活化蛋白激酶 (MEK) 及胞外信号调节激酶 (ERK) 的特异性级联磷酸化将信号由细胞外传入细胞核内。BRAF是RAF三个亚型之一,是MAPK通路重要的转导因子。在催化底物方面, BRAF以MEK1/2为底物,是MEK最主要的活化激酶。 BRAF在3个亚型

WCC 2014 :免疫肿瘤学:癌症转化医学

澳大利亚黑素瘤患者Ryan Tilly强烈呼吁快速将一些新药物纳入报销/补贴药物行列。最近发生在澳大利亚的一个事例,药物pilimumab(商品名为Yervoy)被纳入药物优惠项目(PBS)用了长达16个月的时间。在这期间,患者不得不自己筹集资金,很多患者或因缺乏资金或因他们的治疗人员疏忽而错过了治疗。就在各种利益相关者忙着协商赔偿条款的同时,却约有350例患者不治而亡。 墨尔本大学和

罗氏、Exelixis计划向FDA提交治疗黑色素瘤新组合疗法

制药巨头罗氏公司和其合作伙伴Exelixis公司最近表示,双方已经向FDA提交其治疗黑色素瘤的联合疗法,FDA已经同意启动加速审批的流程,这一决定将使这一疗法的审批时间由传统的10个月缩短到6个月。这一疗法主要由Exelixis公司开发的cobimetinib和罗氏公司业已上市的Zelboraf组成。此前早些时候,双方已经向欧洲医药管理部门提交了类似的申请。 在最近的一次临床三期研究中,研究人员

J Clin Pathol:KIT突变研究有助于黑色素瘤的个体化治疗

胃肠(GI)道黑色素瘤是非常罕见的肿瘤,通常代表发生于小肠的的转移性疾病。在尸体检查中,43.5%--60%死于黑色素瘤的病人出现胃肠道转移。然而,因为缺少临床症状,只有<5%的胃肠道转移在病人的生存期中诊断出来。原发性粘膜黑色素瘤(MM)大约占了所有的黑色素瘤1.3%。肛门直肠(AR)黑色素瘤构成23.8%的原发性粘膜黑色素瘤,然而,发生在头颈部,女性生殖道和尿道的黑色素瘤的构成比分别为55.4

JCO:达拉菲尼联合曲美替尼治疗黑色素瘤效果显著

目的:临床前及早期的临床试验已经证实BRAF和MEK抑制剂联合治疗BRAF(V600)突变的黑色素瘤患者效果优于单药BRAF抑制剂。该研究评估了达拉菲尼和曲美替尼联合治疗既往接受过BRAF抑制剂的患者的安全性及疗效性。材料及方法:在这个开放性、I/II试验中,我们评估了达拉菲尼和曲美替尼的药理机制、安全性及疗效。该试验报道了联合治疗的结果,包括26例既往接受BRAF抑制剂进展的患者(B组)以及45

Nature:太阳下的黑色素瘤

黑色素瘤是一种由皮肤和其他器官黑素细胞产生的肿瘤,表现为色素性皮损在数月或数年中发生明显改变。临床症状包括出血、瘙痒、压痛、溃疡等,其恶性程度高,转移发生早,死亡率高。全球每年有数以万计的人罹患这种疾病,其发病率攀升的速度比所有其他类型的实体瘤都要快。 最新一期(11月19日)的Nature杂志以“Outlook: Melanoma”为题,以九篇文章的形式专题介绍了有关黑色素瘤